Diagnosis and prognosis of chondrosarcoma of bone

Expert Review of Molecular Diagnostics

Volumn 2, Issue 5, 2002, Pages 461-472

  Rozeman, Leida B ^a   Hogendoorn, Pancras C W ^a   Bovée, Judith V M G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chondrosarcoma; Diagnosis; Enchondroma; Genetics; Osteochondroma; Prognosis

Indexed keywords

ANGIOGENESIS; CANCER GRADING; CANCER SIZE; CANCER STAGING; CHONDROSARCOMA; CLINICAL EXAMINATION; DIAGNOSTIC IMAGING; DNA DETERMINATION; FLOW CYTOMETRY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; REVIEW;

EID: 0036712403     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.2.5.461     Document Type: Review

References (97)

1. Bone tumors. Diagnosis, treatment and prognosis
2. Chondrosarcoma of bone: An assessment of outcome
3. Chondrosarcoma: A review
4. Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading
5. Risk factors for survival and local control in chondrosarcoma of bone
6. Primary chondrosarcoma of long bones and limb girdles
7. Usefulness of radiography in differentiating enchondroma from central Grade I chondrosarcoma
8. A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases
9. Benign and malignant cartilage tumors of bone and joint: Their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology I. The intramedullary cartilage tumors
10. Cartilaginous tumors: Correlation of gadolineum-enhanced MR imaging and histopathologic findings
11. Definitions of osteosarcoma, chondrosarcoma and fibrosarcoma of bone
12. Diagnosis of borderline cartilage lesions of bone
13. Cartilaginous tumors: Fast contrast-enhanced MR imaging
14. Microvasculature and VEGF expression in cartilaginous tumors
15. Diagnostic impact of histologic parameters in dedifferentiating enchondroma from grade I central chondrosarcoma
16. Upregulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma
17. PTHrP and Bcl-2: Essential regulatory molecules in chondrocyte differentiation and chondrogenic tumors
18. Platelet-derived growth factor-α receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome
19. Dyschondroplasie
20. Maffucci's syndrome: Clinical and radiological features of a rare condition
21. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma
22. A mutant PTH/PTHrP Type I receptor in enchondromatosis
23. Possible association of p53 overexpression and mutation with high-grade chondrosarcoma
24. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas
25. Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas
26. p53 mutations in chondrosarcoma
27. Altered p53 is associated with aggressive behavior in chondrosarcoma: A long-term follow-up study
28. Chromosome 9 alterations and trisomy 22 in central chondrosarcoma: A cytogenetic and DNA flow cytometric analysis of chondrosarcoma subtypes
29. Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma
30. Changes in p14(ARF) do not play a primary role in human chondrosarcoma tissues
31. Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues
32. The natural history of hereditary multiple exostoses
33. Natural history study of hereditary multiple exostoses
34. Cloning of the putative turnout suppressor gene for hereditary multiple exostoses (EXT1)
35. Genetic heterogeneity in families with hereditary multiple exostoses
36. The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes
37. Positional cloning of a gene involved in hereditary multiple exostoses
38. A gene for hereditary multiple exostoses maps to chromosome 19p
39. Hereditary multiple exostoses (EXT): Mutational studies of familial EXT1 cases and EXT-associated malignancies
40. Loss of heterozygosity in chondrosarcomas for markers linked to hereditary multiple exostoses loci on chromosomes 8 and 11
41. Hereditary multiple exostosis and chondrosarcoma: Linkage to chromosome 11 and loss of heterozygosity for EXT-linked markers on chromosomes 11 and 8
42. Diminished levels of the putative tumor suppressor proteins EXT1 and EXT2 in exostosis chondrocytes
43. EXT-mutation analysis and loss of heterozygosiry in sporadic and hereditary osteochondromas and secondary chondrosarcomas
44. Near-haploidy and subsequent polyploidization characterize the progression of peripheral chondrosarcoma
45. The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate
46. The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate
47. EXT1 gene mutation induces chondrocyte cytoskeletal abnormalities and defective collagen expression in the exostoses
48. Parathyroid hormone-related protein and Indian hedgehog control the pace of cartilage differentiation
49. Expression of Indian Hedgehog, PTHrP and their receptors in the postnatal growth plate of the rat: Evidence for a locally acting growth restraining feedback loop after birth
50. Bcl-2 expression as a diagnostic marker to identify malignant progression of osteochondroma
51. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas
52. Dedifferentiaated chondrosarcoma
53. Radiological features of 24 periosteal chondrosarcomas
54. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma
55. Treatment and outcome of recurrent pelvic chondrosarcoma
56. Chondrosarcoma of the phalanx: A locally aggressive lesion with minimal metastatic potential. A report of 35 cases and a review of the literature
57. CoUagenase specificity in chondrosarcoma metastasis
58. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor
59. Expression of metalloproteinases and tissue inhibitor in cartilaginous neoplasms of bone
60. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas
61. Expression of membrane Type 1 matrix metalloproteinase, matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 in human cartilaginous tumors with special emphasis on mesenchymal and dedifferentiated chondrosarcoma
62. Matrix metalloproteinase digestion of aggrecan in human cartilage turnouts
63. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma
64. Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis and survival in human chondrosarcoma
65. To the editor: Association between ratio of matrix metalloproteinase-1 and local recurrence, metastasis and survival in human chondrosarcoma
66. Cysteine proteinases in chondrosarcomas
67. Prognostic significance of Ki-67 (MIB1) proliferation index and p53 overexpression in chondrosarcomas
68. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma
69. Cytogenetic aberrations and their prognostic impact in chondrosarcoma
70. Assessment of malignancy of cartilage tumors using flow cytometry. A preliminary report
71. p53 expression and DNA ploidy of cartilage lesions
72. Cyrophotometric studies of the nuclear DNA content in cartilaginous tumors
73. Flow cytometric determination of DNA content in malignant and benign bone tumours
74. Prognostic factors in chondrosarcoma: A comparative study of cellular DNA content and clinicopathologic features
75. Flow DNA analysis of primary bone tumors. Relationship between cellular DNA content and histopathologic classification
76. Usefulness of cytofluorometric DNA ploidy analysis in distinguishing benign cartilaginous tumors from chondrosarcomas
77. The use of flow cytometry in assessing malignancy in bone and soft tissue tumors
78. Flow cytometric analysis of DNA in bone and soft-tissue tumors using nuclear suspensions
79. p53 expression in dedifferentiated chondrosarcoma
80. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas
81. Chondrosarcoma of bone: Analysis of 108 cases and evaluation for predictors of outcome
82. Chondrosarcoma of bone: An oncological and functional follow-up study
83. Expression of bone morphogenetic proteins and receptors in sarcomas
84. Heat shock protein 72 expression in chondrosarcoma correlates with differentiation
85. Expression of connective tissue growth factor in cartilaginous tumors
86. Clinical relevance of Ki-67 expression in bone tumors
87. Immunohistochemical localization of collagenous proteins in cartilaginous tumors: Characteristic distribution of Type IX collagen
88. Angiogenic cytokines in cartilage tumors
89. Immunohistochemical analysis of nm 23 protein expression in malignant bone tumors
90. Relationship of p21 (waf1/cip1) and differentiation in chondrosarcoma cells
91. Chemotherapy and P-glycoprotein expression in chondrosarcoma
92. Amplification of the c-myc proto-oncogene in human chondrosarcoma
93. Abl expression, tumour grade and apoptosis in chondrosarcoma
94. Chondrosarcoma of bone. A clinical and DNA flow cytometric study
95. PTEN mutation is rare in chondrosarcomo
96. Frequent loss of heterozygosity for markers on chromosome arm 10q in chondrosarcomas